Molecular structure of STX64, CAS Number: 288628-05-7
STX64 (CAS 288628-05-7)
Alternate Names:
667 Coumate; BN 83495
Application:
STX64 is a potent, irreversible inhibitor of ES (steroid sulfatase)
CAS Number:
288628-05-7
Purity:
≥98%
Molecular Weight:
309.34
Molecular Formula:
C14H15NO5S
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
STX64 emerges as a novel synthetic small molecule compound specifically designed to target and impede the activity of histone deacetylase (HDAC). In vitro studies have demonstrated its ability to inhibit HDAC activity in cell cultures. STX64 achieves its impact by suppressing the activity of HDAC, an enzyme pivotal in the regulation of gene expression. HDAC functions by removing acetyl groups from histones, proteins that play a role in DNA packaging.
STX64 (CAS 288628-05-7) References
- In vivo efficacy of STX213, a second-generation steroid sulfatase inhibitor, for hormone-dependent breast cancer therapy. | Foster, PA., et al. 2006. Clin Cancer Res. 12: 5543-9. PMID: 17000691
- The use of steroid sulfatase inhibitors as a novel therapeutic strategy against hormone-dependent endometrial cancer. | Foster, PA., et al. 2008. Endocrinology. 149: 4035-42. PMID: 18450955
- Inhibition of steroid sulphatase activity via the percutaneous route: a new option for breast cancer therapy. | Purohit, A., et al. 2008. Anticancer Res. 28: 1517-23. PMID: 18630506
- Inhibition of steroid sulfatase activity in endometriotic implants by STX64 (667Coumate): a potential new therapy. | Fusi, L., et al. 2008. ScientificWorldJournal. 8: 1325-7. PMID: 19112542
- The development of steroid sulfatase inhibitors for hormone-dependent cancer therapy. | Day, JM., et al. 2009. Ann N Y Acad Sci. 1155: 80-7. PMID: 19250195
- Effect of tamoxifen or anastrozole on steroid sulfatase activity and serum androgen concentrations in postmenopausal women with breast cancer. | Stanway, SJ., et al. 2011. Anticancer Res. 31: 1367-72. PMID: 21508387
- Structure-activity relationship for the first-in-class clinical steroid sulfatase inhibitor Irosustat (STX64, BN83495). | Woo, LW., et al. 2011. ChemMedChem. 6: 2019-34. PMID: 21990014
- Sulfatase inhibitors: a patent review. | Williams, SJ. 2013. Expert Opin Ther Pat. 23: 79-98. PMID: 23136854
- Evidence of estrone-sulfate uptake modification in young and middle-aged rat prostate. | Giton, F., et al. 2015. J Steroid Biochem Mol Biol. 152: 89-100. PMID: 25958048
- Estrone sulfate and dehydroepiandrosterone sulfate: Transactivation of the estrogen and androgen receptor. | Bjerregaard-Olesen, C., et al. 2016. Steroids. 105: 50-8. PMID: 26666359
- SULFATION PATHWAYS: A role for steroid sulphatase in intracrine regulation of endometrial decidualisation. | Gibson, DA., et al. 2018. J Mol Endocrinol. 61: M57-M65. PMID: 29720512
- Steroid hormones sulfatase inactivation extends lifespan and ameliorates age-related diseases. | Pérez-Jiménez, MM., et al. 2021. Nat Commun. 12: 49. PMID: 33397961
- Steroid Sulphatase and Its Inhibitors: Past, Present, and Future. | Foster, PA. 2021. Molecules. 26: PMID: 34064842
- Bisphenol A-sulfate conjugate disrupts AURKA transcription and cell cycle in BeWo cytotrophoblasts. | Fujiki, J., et al. 2022. Mol Cell Endocrinol. 545: 111561. PMID: 35041905
Inhibitor of:
ES.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
STX64, 5 mg | sc-255625 | 5 mg | $213.00 |